Avsnittsbeskrivning
A quiet week for top-tier acromegaly papers, with a useful surgical-outcome predictor and a new treatment-landscape review, while rare disease industry news was dominated by setbacks: a failed Becker muscular dystrophy trial, deep Ultragenyx layoffs, and a new safety signal for Zolgensma.

